Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Awarded US Patent

Premium
Luminex has been awarded US Patent 7,318,336, “Methods for controlling one or more parameters of a flow cytometer type measurement system.”
 
The inventors listed on the patent are Wayne Roth and Douglas Moore.
 
The patent provides methods for controlling one or more parameters of a flow cytometer-type measurement system, the abstract stated. One method involves monitoring parameter(s) of the system during measurements of sample microspheres. This method also involves altering the parameter(s) in real time based on the monitoring. A second method includes monitoring a temperature proximate to the measurement system, such as altering a bias voltage of an avalanche photo diode in response to the temperature using empirically derived data. Output signals of a photomultiplier tube could also be altered in response to the temperature using a characteristic curve. Other methods include monitoring a temperature of a fluid, in which sample microspheres are disposed, that will flow through the flow cytometer-type measurement system. This method would involve determining a velocity of the sample microspheres in the measurement system from a viscosity of the fluid at that temperature.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.